Inhalon Biopharma has announced that it is partnered with Celltrion to develop a nebulized formulation of regdanvimab, a monoclonal antibody for the treatment of COVID-19, which will be known as IN-006. In May 2021, Inhalon announced that it had been awarded a US Army contract worth $7 million for development of IN-006. The company says that a Phase 1 study of IN-006 … [Read more...] about Celltrion, Inhalon partner on inhaled regdanvimab for COVID-19
Medical
Meissa announces results of preclinical testing of its intranasal COVID-19 vaccine, Phase 1 trial update
Meissa Vaccines said that a SARS-CoV-2 challenge test of its MV-014-212 intranasal live attenuated vaccine candidate in non-human primates demonstrated similar efficacy for a single dose compared to currently available vaccines, and the intranasal vaccine stimulated both mucosal and systemic antibodies. According to the company, the vaccine generated antibodies able … [Read more...] about Meissa announces results of preclinical testing of its intranasal COVID-19 vaccine, Phase 1 trial update
AIM ImmunoTech announces planned human challenge trial of intranasal Ampligen against rhinovirus and flu
AIM ImmunoTech has announced a planned Phase 2a human challenge trial of intranasal Ampligen rintatolimod against human rhinovirus and influenza. The company suggested that "Success against these common viruses could also indicate that an Ampligen prophylaxis could help blunt the spread of infection from lethal coronaviruses, as well as other serious viruses." The … [Read more...] about AIM ImmunoTech announces planned human challenge trial of intranasal Ampligen against rhinovirus and flu
Opiant announces positive results from PK study of OPNT003 intranasal nalmefene
Opiant Pharmaceuticals said that a PK study of its OPNT003 intranasal nalmefene, which it is developing for opioid overdose, demonstrated that the Tmax of the nasal formulation was about 15 minutes, similar to that shown in a previous pilot study, and Cmax was slightly higher than for an intramuscular injection of nalmefene and higher than in the pilot study. The … [Read more...] about Opiant announces positive results from PK study of OPNT003 intranasal nalmefene
Washington Research Foundation awards grant for development of inhaled miniprotein for IPF
Anindya Roy, a researcher at the University of Washington Institute for Protein Design (IPD), has received a $250,000 grant from Washington Research Foundation (WRF) for continued development of an inhaled miniprotein binder for the treatment of idiopathic pulmonary fibrosis (IPF), WRF has announced. According to WRF, Roy's miniprotein binds to the αvβ6 integrin, … [Read more...] about Washington Research Foundation awards grant for development of inhaled miniprotein for IPF
Atossa announces Phase 1/2a study of nebulized AT-H201
Atossa Therapeutics said that the Human Research Ethics Committee (HREC) of the Australian National Health and Medical Research Council (NHMRC) has okayed a Phase 1/2a clinical study of the company's nebulized AT-H201, which is "is a proprietary combination of two drugs previously approved by the FDA to treat other diseases and by other administration routes." The … [Read more...] about Atossa announces Phase 1/2a study of nebulized AT-H201
PureIMS, Sever Pharma Solutions, and Radboudumc partner on development of tigecycline DPI
Dutch DPI developer Pure IMS has announced a new partnership with CDMO Sever Pharma Solutions (formerly Disphar International) and Radboud University Medical Center (Radboudumc) for development of a tigecycline dry powder inhaler for the treatment of multi-drug resistant Mycobacterium abscessus lung infections. Radboudumc research has demonstrated that inhaled … [Read more...] about PureIMS, Sever Pharma Solutions, and Radboudumc partner on development of tigecycline DPI
FluGen gets funding from US Department of Defense for intranasal flu vaccine
FluGen said that it has received an $11.4 million grant from the United States Department of Defense for a Phase 1b study to evaluate the ability of its M2SR intranasal flu vaccine to protect against a variety of flu strains, including those like H3N2 that are mismatched to current vaccines. In February 2019, FluGen announced that a Phase 2 trial of the M2SR vaccine … [Read more...] about FluGen gets funding from US Department of Defense for intranasal flu vaccine
Savara initiates new Phase 3 trial of molgramostim inhaled GM-CSF for aPAP
Savara has announced the initiation of the Phase 3 IMPALA-2 clinical trial of molgramostim inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). In December 2020, the company stopped development of the AeroVanc vancomycin DPI and Apulmiq (Linhaliq) inhaled … [Read more...] about Savara initiates new Phase 3 trial of molgramostim inhaled GM-CSF for aPAP
Altimmune halts development of AdCOVID intranasal vaccine, terminates trial of T-COVID intranasal therapeutic
Altimmune has discontinued development of its AdCOVID intranasal vaccine for the prevention of COVID-19 after the failure of a Phase 1 trial and has stopped enrollment in a Phase 1/2 trial of its T-COVID intranasal therapy for COVID-19 the company said. The FDA had cleared the IND for the Phase 1 trial of AdCOVID in February 2021; the Phase 1/2 trial of T-COVID was … [Read more...] about Altimmune halts development of AdCOVID intranasal vaccine, terminates trial of T-COVID intranasal therapeutic